3β-methoxyandrost-5-ene-7,17-dione | 357923-19-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β-methoxyandrost-5-ene-7,17-dione
• 英文别名: 3β-methoxyandrost-5-ene；3beta-Methoxyandrost-5-ene-7,17-dione；(3S,8R,9S,10R,13S,14S)-3-methoxy-10,13-dimethyl-2,3,4,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-7,17-dione
• CAS: 357923-19-4
• 化学式: C₂₀H₂₈O₃
• 分子量: 316.441
• InChiKey: OVZWHWNNRAMDNJ-YUCWNLPMSA-N

物化性质

• 熔点：
  172-175 °C
• 沸点：
  453.1±45.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3β-methoxyandrost-5-ene-7,17-dione 在 sodium tetrahydroborate 、 cerium(III) chloride 作用下， 以 甲醇 为溶剂， 生成 3β-methoxyandrost-5-ene-7β,17β-diol
  参考文献：
  名称：

  Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates

  摘要：

  The 7-oxo derivative of dehydroepiandrosterone is more active than the parent steroid and is devoid of adverse side effects in rats, monkeys and humans. In anticipation of possible therapeutic use we have sought more active, longer lasting forms of 7-oxo- and 7 beta -hydroxydehydroepiandrosterones. The 7-oxo- and 7-hydroxy steroids have been converted to glucuronides, ethers and carbonate esters. The syntheses of these compounds are described and their ability to induce the formation of liver thermogenic enzymes when fed to rats is reported. Some of the new derivatives were found to be somewhat more effective than the equimolar amounts of 7-oxo-DHEA with which they were compared in each experiment. (C) 2001 Elsevier Science Inc. All rights reserved.

  DOI：

  10.1016/s0039-128x(00)00234-8
• 作为产物：
  描述：

  3β-tosyloxyandrost-5-ene-17-one 在 N-羟基邻苯二甲酰亚胺 、 氧气 、 1,1'-偶氮(氰基环己烷) 作用下， 以 乙酸乙酯 、 丙酮 为溶剂， 反应 2.0h， 生成 3β-methoxyandrost-5-ene-7,17-dione
  参考文献：
  名称：

  Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates

  摘要：

  The 7-oxo derivative of dehydroepiandrosterone is more active than the parent steroid and is devoid of adverse side effects in rats, monkeys and humans. In anticipation of possible therapeutic use we have sought more active, longer lasting forms of 7-oxo- and 7 beta -hydroxydehydroepiandrosterones. The 7-oxo- and 7-hydroxy steroids have been converted to glucuronides, ethers and carbonate esters. The syntheses of these compounds are described and their ability to induce the formation of liver thermogenic enzymes when fed to rats is reported. Some of the new derivatives were found to be somewhat more effective than the equimolar amounts of 7-oxo-DHEA with which they were compared in each experiment. (C) 2001 Elsevier Science Inc. All rights reserved.

  DOI：

  10.1016/s0039-128x(00)00234-8

文献信息

• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。
• 7-oxo-DHEA compounds for treating keratinous conditions/afflictions
  申请人：——

  公开号：US20030054021A1

  公开（公告）日：2003-03-20

  7-Oxo-DHEA derivatives, various of which are themselves novel compounds, are well suited for cosmetically/therapeutically treating adverse conditions/afflictions of a keratinous substrate/material, notably of human skin, hair, eyelashes and nails, to improve the appearance thereof, in particular to prevent or treat signs of aging of the skin and/or a dull complexion and/or skin or hair pigmentation disorders and/or dryness of the skin and/or hyperseborrhoea and/or hyperseborrhoea-related imperfections and/or sensitive skin and/or dandruff and/or natural hair loss and/or baldness.

  7-Oxo-DHEA衍生物，其中有许多是新颖的化合物，非常适合用于美容/治疗角质基质/材料的不良状况/疾病，尤其是人类皮肤、头发、睫毛和指甲，以改善外观，特别是预防或治疗皮肤衰老和/或暗沉肤色和/或皮肤或头发色素沉着障碍和/或皮肤干燥和/或皮脂分泌旺盛和/或与皮脂分泌旺盛相关的瑕疵和/或敏感皮肤和/或头皮屑和/或自然脱发和/或秃发。
• Compositions and treatment methods
  申请人：Ahlem N. Clarence

  公开号：US20060079492A1

  公开（公告）日：2006-04-13

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄甾烷可用于治疗方法。
• 15-OXA-steroid compounds
  申请人：Harbor BioSciences, Inc.

  公开号：US07947846B2

  公开（公告）日：2011-05-24

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5 -ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17 -tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17 -tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄烷，这些化合物可用于治疗方法。
• COMPOSITIONS AND TREATMENT METHODS-2
  申请人：Frincke James M.

  公开号：US20100222425A1

  公开（公告）日：2010-09-02

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可以在本发明中使用的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄烷。这些化合物可以用于治疗方法中。